ArticleThe Journal of international medical research2020
The microRNA-152/human leukocyte antigen-G axis affects proliferation and immune escape of non-small cell lung cancer cells.
Article in The Journal of international medical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- MiR-26b-5p mediates radioresistance and immunosuppression via targeting PRKCD in non-small cell lung cancer.Journal of cancer research and clinical oncology · 2025Article
- Regulation and function of microRNA-152 in various types of cancers: its upstream regulators and downstream targets.Clinical and experimental medicine · 2025Review
- Analysis of HLA-G 14 bp Insertion/Deletion Polymorphism and HLA-G, ILT2 and ILT4 Expression in Head and Neck Squamous Cell Carcinoma Patients.Diseases (Basel, Switzerland) · 2024Article
- An HLA-G/SPAG9/STAT3 axis promotes brain metastases.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- HLA-G: Too Much or Too Little? Role in Cancer and Autoimmune Disease.Frontiers in immunology · 2022Review
- DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy.Signal transduction and targeted therapy · 2021Review
- HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers.Frontiers in immunology · 2021Review
- HLA-G 3'UTR Polymorphisms Are Linked to Susceptibility and Survival in Spanish Gastric Adenocarcinoma Patients.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the role of human leukocyte antigen (HLA-G) on proliferation, invasion, and immune escape in non-small cell lung cancer (NSCLC).
methodsThe relationship between HLA-G and overall survival (OS) of NSCLC patients was analyzed using the KMPlot database. The expression of micro (mi)R-152 or HLA-G was modulated by transfecting synthetic oligonucleotides, and the impact of the miR-152/HLA-G axis on proliferation, invasion, colony formation in soft agar, and tolerance to natural killer (NK) cell cytolysis was measured.
resultsBioinformatics analysis showed that high HLA-G expression was correlated with poor OS in NSCLC patients. The tolerance of NSCLC cells to NK cytotoxicity was negatively correlated with HLA-G and positively correlated with miR-152 expression. Over-expressing miR-152 inhibited HLA-G expression in A549 cells and attenuated cell proliferation, migration, colony formation ability, and tolerance to NK cells. However, blocking HLA-G expression by small interfering RNA did not affect migration or colony formation, but only proliferation and tolerance to NK cells
conclusionsmiR-152/HLA-G axis plays an oncogenic role in NSCLC by affecting cell proliferation and immune escape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.